An update of Clinical value of circulating tumor DNA in esophageal cancer: a systematic review and meta- analysis

Author:

Zhang Yaozhong1,Du Huazhen1,Wang Na1,Wang Lei1,Hang Yajie1

Affiliation:

1. the Fourth Hospital of Hebei Medical University

Abstract

Abstract Background Esophageal cancer is a deadly disease with limited therapeutic options. Circulating tumor DNA (ctDNA) could be a promising tool in this regard, although the data is limited. We performed a systematic review and meta-analysis to summarize the clinical applicability of the next-generation sequencing (NGS) and droplet digital polymerase chain reaction (ddPCR) technology on the ctDNA detection of the EC and list its current challenges. Methods We systematically searched MEDLINE (via PubMed), Embase (via OVID), ISI Web of Science database and Cochrane Library from January, 2000 to April, 2023. Progression-free survival (PFS) and overall survival (OS) were set as primary outcome endpoints. Pathologic response was evaluated by tumor regression grade (TRG), accord to the eighth edition of the American Joint Committee on Cancer (AJCC). Major pathologic regression (MPR) was defined as TRG 1 and 2. The MPR was set as secondary endpoint. Hazard rate (HR) and associated 95% CI were used as the effect indicators the association between ctDNA and prognosis of EC. MPR rates were also calculated. Fixed-effect model (Inverse Variance) or random-effect model (Mantel-Haenszel method) was performed depending on the statistically heterogeneity. Results Twenty-two studies, containing 1144 patients with EC, were included in this meta-analysis. The results showed that OS (HR = 3.87; 95% CI, 2.86–5.23) and PFS (HR = 4.28; 95% CI, 3.34–5.48) were worse in ctDNA-positive patients. In the neoadjuvant therapy, the sensitivity analysis showed the clarified HR of ctDNA-positive was 1.13(95% CI, 1.01–1.28). In addition, the estimated MPR rate was 50% (95%CI:14%-86%) of patients changed positive to negative; and 51% (95%CI:33%-69%) for patients kept negative from beginning to end. We also found that TP53, NOTCH1, CCND1 and CNKN2A are most frequent mutation genes. Conclusions Detection of ctDNA had prognostic value for EC patients. Positive ctDNA is associated with poor prognosis. A standardized technique needs to be established in order to introduce ctDNA analysis into routine clinical practice. Longitudinal ctDNA monitoring might be a better strategy in the neoadjuvant therapy. In an era of personalized medicine, ctDNA could be a promising tool to individualize treatment planning and to improve outcomes in esophageal cancer.

Publisher

Research Square Platform LLC

Reference66 articles.

1. Cancer statistics, 2023;Siegel RL;Cancer J Clin,2023

2. [Cancer statistics in China, 2016];Zheng RS;Zhonghua zhong liu za zhi [Chinese journal of oncology],2023

3. Esophageal cancer: emerging therapeutics;Rogers JE;Expert Opin Ther Targets,2022

4. Cancer statistics in China and United States, 2022: profiles, trends, and determinants;Xia C;Chin Med J,2022

5. Recent progress in multidisciplinary treatment for patients with esophageal cancer;Watanabe M;Surg Today,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3